EU and US could reach trade deal this weekend - Reuters
Tuesday, shares of Amgen (NASDAQ:AMGN) were in focus following a reaffirmation of a Neutral rating and a steady price target of $305.00 by analysts at Cantor Fitzgerald. Currently trading at $273.68, InvestingPro analysis suggests the stock is fairly valued. The firm’s position comes with an assessment of the biopharmaceutical company’s growth prospects, particularly concerning its product MariTide.
The analysts at Cantor Fitzgerald expressed a cautious outlook on Amgen’s ability to enhance its long-term growth rate through MariTide, given the significant valuation already attributed to the product. However, recent data from InvestingPro shows strong fundamentals, with revenue growth of 18.57% and six analysts revising earnings estimates upward for the upcoming period. According to their evaluation, the potential for MariTide to significantly alter Amgen’s growth trajectory is limited.
Amgen, known for its biotechnological innovations, has been closely watched by investors for its product pipeline and market performance. The company’s focus on developing novel therapies has often been a point of interest for the biopharmaceutical industry.
The confirmation of the Neutral rating indicates that Cantor Fitzgerald does not foresee a substantial change in Amgen’s market position in the near term. Moreover, the $305.00 price target suggests that the analysts believe the stock is fairly valued at its current level.
Investors and stakeholders in Amgen will continue to monitor the company’s performance, especially any developments regarding MariTide and its impact on Amgen’s market valuation. The company maintains a robust dividend yield of 3.48% and has raised dividends for 14 consecutive years. The feedback from Cantor Fitzgerald provides a snapshot of the firm’s expectations for Amgen’s financial outlook. For deeper insights into Amgen’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Amgen has reported significant developments across various aspects of its business. The company announced that its Phase 3 DeLLphi-304 trial for IMDELLTRA in small cell lung cancer patients met its primary endpoint, showing a statistically significant improvement in overall survival over standard chemotherapy. This trial result reinforces IMDELLTRA as a standard of care, with Amgen planning to present detailed data at an upcoming medical congress. In addition, Amgen received FDA approval for Uplizna to treat IgG4-related disease, marking the first drug approved for this condition, and potentially providing a new revenue stream.
Analyst firms have also weighed in on Amgen’s prospects. Piper Sandler maintained an Overweight rating with a price target of $329, highlighting the potential of MariTide and Uplizna’s role in Amgen’s growth trajectory. Meanwhile, UBS raised its price target to $319 while keeping a Neutral rating, noting Amgen’s strong performance and projecting solid first-quarter financial results. Cantor Fitzgerald also resumed coverage with a Neutral rating, citing mixed prospects for Amgen, particularly around its obesity treatment, MariTide.
The company’s first-quarter revenues and earnings are projected to align closely with consensus estimates, with revenues expected at $8.11 billion and earnings per share at $4.30. Despite challenges, Amgen’s key growth driver, Repatha, continues to perform well in the market. These developments reflect Amgen’s ongoing efforts to strengthen its position in the competitive biotechnology landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.